BIONTECH SE SPON. ADRS 1
Commented by Mario Hose on January 11th, 2022 | 11:36 CET
Trading stocks in focus: BioNTech, Darktrace, EXMceuticals
Tuesday is under a good omen on the stock market after a failed start to the week. Germany's leading index, the DAX, is trading at 15,961 points, up around 0.32%, but has not yet made it above the psychological 16,000 mark. The MDAX last traded at 34,713 points (+0.42%), TexDAX at 3,661 points (+1.09%) and SDAX at 15,913 points with 0.66% in the plus.
Read
Commented by Mario Hose on January 10th, 2022 | 12:02 CET
Trading stocks in focus: Aspermont, BASF, BioNTech
At the beginning of the week, the DAX is currently trading around 0.19% down at 15,939 points and thus remains below the psychological mark of 16,000 points. The MDAX recently traded again below the 35,000 mark at 34,804 points (-0.52%), TexDAX at 3,653 points (-1.50%) and SDAX at 15,936 points with 1.06% in the red. Overall, the indices had given back their initial gains from the start of trading and are trading in negative territory in the morning.
Read
Commented by André Will-Laudien on January 10th, 2022 | 10:22 CET
Tembo Gold, BioNTech, Valneva, MorphoSys - Turnaround or crash?
At the beginning of the year, there is much talk about the seemingly eternally running stock markets and the infinite wealth of those who have done everything right. Of course, shorting Tesla was a risk; it went wrong 85% of the time. However, since the "minutes" of the Federal Reserve, it is perhaps not a new short with the announcement. Because interest rates will probably have to rise once the tapering gets going. Incidentally, opinions are divided on the inflation trend: some banks estimate a 1 before the decimal point, others see a 5. So what now? Interest rates up mean problems for growth stocks; interest rates down could mean a continuation of the bull market. We take a look at interesting shares with their own stories.
Read
Commented by Mario Hose on January 7th, 2022 | 16:04 CET
Trading shares in focus: Allianz, BioNTech, BrainChip
At the end of the week, the DAX was down around 0.37% at 15,968 points and thus below the psychological mark of 16,000 points. The MDAX last traded at 35,002 points (-34%), TexDAX at 3,731 points (-0.36%) and SDAX at 16,125 points with 0.92% in the red.
Read
Commented by Nico Popp on January 7th, 2022 | 12:51 CET
BioNTech, XPhyto, Valneva: 3 stocks for next week?
Omicron is slowly but surely making its presence felt in Germany. After the holidays, when first there is less testing, and secondly the fax machines in German health offices are at a standstill, the official statistics are becoming a little more accurate again. There are already signs of where the journey might be headed. If the past week's growth remains constant, the incidence could already be above the 500 mark in 7 to 10 days. Although such projections are subject to error, it is worth looking at the typical pandemic stocks.
Read
Commented by Fabian Lorenz on January 6th, 2022 | 11:26 CET
The beginning of the end at BioNTech? Positive start for JinkoSolar and Diamcor
Is Omicron the beginning of the end of the Corona pandemic? Not only stock market players are asking themselves this question. Because as it seems, the virus variant is more contagious but seemingly leads to less severe sickness. As a result, the shares of vaccine manufacturers such as BioNTech, Moderna and Valneva have recently suffered. However, there are positive things to report, especially for BioNTech. While the Mainz-based Company is optimizing its vaccine for the Omicron variant, there is also positive news from the USA. Not only the COVID-19 vaccine is in demand worldwide, but also diamonds. Most recently, Israel reported a significant increase in demand. Tiffany & Co. partner Diamcor is benefiting from this demand. JinkoSolar's share price is heading north again in the first few days of trading after the heavy losses before Christmas. The IPO of the subsidiary is taking shape.
Read
Commented by André Will-Laudien on December 28th, 2021 | 07:15 CET
BioNTech, Pfizer, Defence Therapeutics, Valneva - The Corona year 2022 is coming
The German government has moved its goal of vaccinating 80% of the population against the coronavirus at least once into the new year. The targeted quota is now to be achieved by the end of January, a government spokesman told the press. The background is that only 73.4% of the population has been vaccinated so far, and the missing 5.3 million first-time vaccinations could hardly be achieved by January 7. The interim goal of 30 million vaccinations by the end of the year, on the other hand, will most likely be met after Christmas, government sources say. The general vaccination obligation is to come on the agenda of the Federal Parliament in the first meeting week in the new year. Thus also the year 2022 will stand under the star "Corona". The following shares are part of the orchestra.
Read
Commented by Nico Popp on December 22nd, 2021 | 13:50 CET
BioNTech, Novavax, Cardiol Therapeutics: This pandemic profiteer is as cheap as can be
Omicron is coming; that much seems certain. But what does the virus mean for the stock market? Currently, the forecasts of the modelers are dominating the news. While some see it as scaremongering, others consider epidemiological models a rational approximation of what we face. Like a crystal ball, so to speak, but without the hocus-pocus. To assess the situation as an investor, it makes sense to assume neither the best nor the worst. We analyze the current viral situation and explain what this could mean for typical Corona stocks.
Read
Commented by André Will-Laudien on December 21st, 2021 | 13:54 CET
Troilus Gold, Valneva, Moderna, BioNTech - Where will these stocks be in 2022?
The winners in the 2021 investment year have undeniably been the hydrogen, lithium and vaccine stocks. They temporarily gained up to 2,000% but also corrected by more than 50% in some cases. These value developments were not always fundamentally justified. Often the assumption of future achievements was sufficient for a corresponding positive development. In the case of the vaccine manufacturers, the stock market players' fantasies were fulfilled; in the case of hydrogen, this statement was valid at least for a 3-month window at the beginning of the year. Unfortunately, the year was disappointing for most gold explorers, as the precious yellow metal was unable to capitalize on the great uncertainty since the outbreak of the pandemic with a price increase. But this could change in 2022 ad hoc!
Read
Commented by Stefan Feulner on December 21st, 2021 | 13:03 CET
BioNTech, Memiontec, Bayer - Catastrophic conditions
There is no question that the Corona pandemic must be fought by all means. Nevertheless, apart from the virus and the question of vaccination, testing and boosters, there are far worse problems on our planet. For example, did you know that in the top daily news, it is reported that some 2.2 billion people have no sustainable, safe and readily available access to drinking water? Or that 361,000 children under the age of five die each year from diarrheal diseases caused by dirty water and contaminated food? The issue of water will be increasingly prominent in the headlines over the next few years. You can already invest in tomorrow's winners.
Read